Evidence map›Paper›PMID 39616473›Full record

ReviewJournal of infection in developing countries2024

The impact of HIV antiretroviral therapy on gut microbiota: the need for well-designed longitudinal studies.

Oumar Dolo, Fousseini Coulibaly, Anou M Somboro, Djeneba B Fofana, Josue Togo, Aliou Balde, Dramane Diallo, Aminata Maiga, Bassirou Diarra, Robert L Murphy and 5 more

Abstract readReview
In one paragraph

Review in Journal of infection in developing countries, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Oumar DoloUniversity Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Fousseini CoulibalyMedical Biology Laboratory of the Point G University Hospital Center, Bamako, Mali.
Anou M SomboroUniversity Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Djeneba B FofanaUniversity Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Josue TogoUniversity Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Aliou BaldeUniversity Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Dramane DialloUniversity Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Aminata MaigaMedical Biology Laboratory of the Point G University Hospital Center, Bamako, Mali.
Bassirou DiarraUniversity Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Robert L MurphyInstitute for Global Health, Northwestern University, Chicago, IL, United States.
Saidou BalamDepartment of Internal Medicine II - Nephrology, University Hospital Regensburg, 93053, Regensburg, Germany.
Jane HollDepartment of Neurology, University of Chicago, Chicago, IL, United States.
Mariam SyllaGabriel TOURE University Hospital, Bamako, Mali.
Mamoudou MaigaUniversity Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Almoustapha I MaigaUniversity Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.

Funding

Partnership for Global Health Research Training Program (Renewal)-Supplement for OBSSR, NCI, NCI-AIDS and NIDCDD43TW010543 · FIC · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Wafaie W Fawzi, DAVIDSON HOWES HAMER · 2017 to 2026
$12.1M
Vanderbilt University-CIDRZ AIDS International Training and Research ProgramD43TW001035 · FIC · VANDERBILT UNIVERSITY · PI VERMUND, STEN H. · 1998 to 2014
$10.9M
HIV and Mycobacterial Disease in MaliD43TW010350 · FIC · UNIV OF SCIENCES, TECH & TECH OF BAMAKO · PI MAIGA, ALMOUSTAPHA ISSIAKA, MURPHY, ROBERT LEO · 2016 to 2025
$3.0M
Development of a Multiplex Quantitative PCR Assay for HIV and Hepatitis B Virus, for Low- and middle Income CountriesK43TW011957 · FIC · UNIV OF SCIENCES, TECH & TECH OF BAMAKO · PI FOFANA, DJENEBA BOCAR · 2021 to 2025
$499k
Metabolic and Immune Consequences of Antibiotic-Related Microbiome Alterations during TB TreatmentR21AI148033 · NIAID · NORTHWESTERN UNIVERSITY · PI MAIGA, MAMOUDOU · 2019 to 2020
$440k
FIC NIH HHS D43 TW001035FIC NIH HHS D43 TW010350FIC NIH HHS D43 TW010543FIC NIH HHS K43 TW011957NIAID NIH HHS R21 AI148033
6 · The paper itself

Abstract

introductionHuman immunodeficiency virus (HIV) infection remains a major public health concern despite a significant decline in HIV-related mortality and morbidity. These significant advances are linked mostly to effective antiretroviral therapy (ART). However, these treatments are not without consequences on other microorganisms in our body, especially when they must be used for life. Balanced gut microbiota is essential for maintaining human health through symbiotic relationship with the host cells. AIMS AND METHODOLOGY: This review focuses on ART and its potential impact on the intestinal microbial population of HIV-infected individuals. Therefore, we retrieved studies focusing on the impact of HIV ART on the gut microbiota, that were published from 2010 to 2021.

resultsIt was observed that most studies on HIV ART and associated gut microbiota have been cross-sectional, and the findings, in general, showed significant damages caused by the ART to the gut microbial community (dysbiosis), with the impact varying in different studies. These changes also revealed dysfunction in microbial translocation and some immune markers, including T lymphocyte rates and the overall inflammation balance.

conclusionsThere are significant gaps in our understanding of the impact of HIV ART on gut microbiota. Thus, a longitudinal study is likely needed with a considerable sample size from different settings and classes of ART to better understand the impact of HIV ART on the gut microbiota, and develop remedial (restorative) and adjunctive host-directed strategies during HIV ART.

Indexed as

DysbiosisGastrointestinal MicrobiomeHIV InfectionsAnti-HIV AgentsAnti-Retroviral AgentsCross-Sectional StudiesHumansLongitudinal StudiesAnti-HIV AgentsAnti-Retroviral AgentsHIV antiretroviral-therapylongitudinal studiesmicrobiota dysbiosis

Identifiers

PMID39616473
PMCPMC12022512

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.